Abstract
The aim of this study was to evaluate the effect of low-dose heparin infusion on arterialized endothelin-1 (ET-1) release in the presence of fasting or high insulin levels in healthy humans. Eleven normal subjects underwent two tests in random order lasting 240 minutes. A primed (250 IU), continuous heparin (600 IU/h) infusion was performed in test 1; saline was infused in test 2 as control. At 120 minutes, a euglycemic hyperinsulinemic clamp (25 mU.kg-1.h-1) was started that lasted 2 hours in both tests. Two hours after heparin infusion (test 1), ET-1 levels decreased by 32% (3.52 +/- 0.60 to 3.02 +/- 0.73 pg/mL), while nitric oxide (NO) and forearm blood flow increased by 29% and 14%, respectively. During saline infusion, ET-1, nitric oxide, and forearm blood flow remained unchanged. There was a significant interaction between the effect of decreasing ET-1 levels and the heparin treatment (F, 4.06; df, 3.30; P < .01). The decrease in ET-1 levels was significantly correlated with the increase in forearm blood flow in test 1 (r = .74; P < .01) but not in test 2. During the heparin/insulin period, ET-1 increased by 25%, returning to fasting values; nitric oxide levels increased by 12%; and forearm blood flow remained unchanged. ...Continue Reading
References
May 28, 1977·Lancet·M J MantM G Grace
Sep 1, 1979·The American Journal of Physiology·R A DeFronzoR Andres
Jan 23, 1992·The New England Journal of Medicine·V FusterJ H Chesebro
Feb 1, 1992·Hypertension·T F LüscherZ H Yang
Oct 13, 1991·The New England Journal of Medicine·A LermanJ C Burnett
Sep 1, 1991·Metabolism: Clinical and Experimental·P M PiattiG Pozza
Jan 18, 1990·The New England Journal of Medicine·Y SaitoH Imura
Mar 8, 1990·Nature·T WatanabeA Imada
Mar 31, 1988·Nature·M YanagisawaT Masaki
Jul 1, 1989·Lancet·T MiyauchiT Masaki
Oct 28, 1989·Lancet·P VallanceS Moncada
Apr 25, 1987·Lancet·G G Neri SerneriA Fortini
Mar 1, 1982·The American Journal of Cardiology·P L WhitlowC E Rackley
Jan 1, 1993·Journal of Cardiovascular Pharmacology·K YokokawaT Takeda
Jun 1, 1995·Diabetologia·L D MontiC Cobelli
Jan 20, 1995·Analytical Biochemistry·C P VerdonR L Prior
May 13, 1995·Lancet·G G Neri SerneriB Magnani
Sep 24, 1994·Lancet·W G Haynes, D J Webb
Nov 19, 1994·Lancet·A M ZeiherH E Schaefer
Jul 1, 1994·Metabolism: Clinical and Experimental·K MetsärinneF Fyhrquist
Aug 1, 1993·Metabolism: Clinical and Experimental·H A WolpertD C Simonson
Oct 1, 1993·The Journal of Clinical Investigation·K YokokawaT Takeda
Sep 1, 1993·Metabolism: Clinical and Experimental·G AnfossiM Trovati
Mar 1, 1996·Diabetes·P M PiattiG Pozza
Oct 1, 1996·Diabetes·T UtriainenH Yki-Järvinen
Citations
Feb 2, 2002·Journal of the American College of Cardiology·Gabriele FragassoSergio Chierchia
Mar 16, 2002·European Journal of Clinical Investigation·T-M LeeC-H Tsai
Feb 4, 2011·The Journal of Clinical Endocrinology and Metabolism·Thomas P J SolomonJohn P Kirwan
Dec 8, 2007·Drugs·Ram WeissItamar Raz
Jul 4, 2003·Canadian Journal of Physiology and Pharmacology·Bruno Battistini
Jul 27, 1999·Metabolism: Clinical and Experimental·A SurdackiJ C Froelich
Mar 16, 2000·Renal Failure·E N Wardle
Dec 17, 2002·Critical Care Medicine·Eduardo R C SchifferDenis R Morel
Oct 8, 1999·Clinical Pharmacology and Therapeutics·O TangphaoB B Hoffman